Insulet Corporation $PODD Shares Sold by Swiss Life Asset Management Ltd

Swiss Life Asset Management Ltd lessened its stake in Insulet Corporation (NASDAQ:PODD) by 40.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,073 shares of the medical instruments supplier’s stock after selling 8,131 shares during the quarter. Swiss Life Asset Management Ltd’s holdings in Insulet were worth $3,727,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Winnow Wealth LLC acquired a new position in shares of Insulet in the 3rd quarter worth approximately $862,000. Machina Capital S.A.S. acquired a new stake in shares of Insulet during the 3rd quarter valued at approximately $2,778,000. Jain Global LLC lifted its stake in Insulet by 148.2% during the third quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock worth $32,945,000 after purchasing an additional 63,719 shares during the last quarter. ING Groep NV lifted its stake in Insulet by 88.5% during the third quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock worth $5,341,000 after purchasing an additional 8,123 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in Insulet by 38.1% in the third quarter. Fisher Asset Management LLC now owns 46,273 shares of the medical instruments supplier’s stock worth $14,286,000 after purchasing an additional 12,754 shares during the period.

Wall Street Analyst Weigh In

A number of analysts have weighed in on PODD shares. Sanford C. Bernstein dropped their target price on shares of Insulet from $380.00 to $330.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. Oppenheimer lowered their price objective on shares of Insulet from $365.00 to $300.00 and set an “outperform” rating for the company in a research report on Thursday, February 19th. BTIG Research reiterated a “buy” rating and set a $380.00 price objective on shares of Insulet in a research note on Wednesday, February 18th. Barclays restated an “underweight” rating and issued a $286.00 target price on shares of Insulet in a research note on Thursday, February 19th. Finally, Zacks Research lowered Insulet from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. Twenty investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus target price of $354.24.

Insiders Place Their Bets

In other Insulet news, Director Michael R. Minogue purchased 2,030 shares of Insulet stock in a transaction on Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the transaction, the director owned 17,483 shares of the company’s stock, valued at $4,304,839.09. The trade was a 13.14% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.39% of the stock is owned by insiders.

Insulet Price Performance

NASDAQ PODD opened at $227.10 on Monday. The company has a 50-day moving average price of $252.11 and a two-hundred day moving average price of $292.83. Insulet Corporation has a 52 week low of $216.49 and a 52 week high of $354.88. The stock has a market cap of $15.99 billion, a price-to-earnings ratio of 64.89, a price-to-earnings-growth ratio of 1.36 and a beta of 1.42. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The company had revenue of $783.80 million for the quarter, compared to analysts’ expectations of $768.31 million. During the same quarter in the previous year, the company posted $1.15 earnings per share. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. Analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.